

INTRALIPID-IODINE FOR IMAGING

Inventor: Joseph ELDOR

FIELD OF THE INVENTION

[0001] The present invention relates to the field of imaging using intralipid-based compounds. Specifically, the present invention relates to intralipid-iodine compounds and compositions for use in imaging, such as hysterosalpingography in infertile women, X-ray imaging with contrast materials.

SUMMARY OF THE INVENTION

[0002] The present invention provides a novel approach for imaging procedures that utilizes contrast materials, such as hysterosalpingography in infertile women, X-ray imaging, cardiac- and limbs-catheterization. Specifically, the present invention provides a multidisciplinary and multipotent intralipid-iodine compounds and compositions for use in imaging that utilizes contrast materials.

DETAILED DESCRIPTION OF THE INVENTION

[0003] Intravenous lipid emulsions have been used experimentally since at least the 19th century. An early product marketed in 1957 under the name Lipomul was briefly used in the United States but was subsequently withdrawn due to side effects. Intralipid was invented by the Swedish physician and nutrition researcher Arvid Wretling, and was approved for clinical use in Sweden in 1962 (Hallberg *et al.*, 1967). In the United States, the Food and Drug Administration initially declined to approve the product due to prior experience with another fat emulsion. It was approved in the United States in 1972.

[0004] Tubal disease is the cause of female infertility in approximately 30% of women (Juras *et al.*, 2002) and 10-25% of these are due to proximal tubal obstruction (Elstein *et al.*, 2008). Selective salpingography represent an approach in the diagnosis and treatment of proximal tubal abnormalities. Intralipid is a synthetic product composed of 10 % soybean oil, 1,2 % egg yolk phospholipids, 2.25 % glycerin, and water. When indicated, intralipid is infused 7-10 days prior to embryo transfer. Rates of ongoing pregnancy and live births were higher among women who underwent

hysterosalpingography (HSG) with oil contrast than among women who underwent this procedure with water contrast.

[0005] It is the first time that intralipid-iodine is suggested to be used for HSG in infertile women.

[0006] The common indications for selective salpingography are to differentiate spasm from true obstruction (Thurmond *et al.*, 2000). In addition to that, it allows clarifying findings from an equivocal hysterosalpingogram. Isthmic as well as intamural blockages were included. The tubal obstruction may be due to amorphous materials occluding the tubal lumen, inflammatory changes and adhesions (Papaioannou *et al.*, 2003). The use of selective salpingography and fallopian tube recanalization has revolutionized the diagnosis and treatment of infertility. Diagnostic procedure has been used since 1980 (Thurmond *et al.*, 2000). It consists on opacification of the fallopian tube directly through a catheter placed in the tubal ostium. The objective is to differentiate spasm from true obstruction and to clear it with a catheter and guide wire system.

[0007] Pregnancy rates among infertile women have been reported to increase after HSG, but it is unclear whether the type of contrast medium used (oil-based or water-soluble contrast) influences this potential therapeutic effect.

[0008] Dreyer *et al.* (2017) performed a multicenter, randomized trial in 27 hospitals in the Netherlands in which infertile women who were undergoing HSG were randomly assigned to undergo this procedure with the use of oil-based or water-based contrast. Subsequently, couples received expectant management or the women underwent intrauterine insemination. The primary outcome was ongoing pregnancy within 6 months after randomization. Outcomes were analyzed according to the intention-to-treat principle.

[0009] A total of 1119 women were randomly assigned to HSG with oil contrast (557 women) or water contrast (562 women). A total of 220 of 554 women in the oil group (39.7%) and 161 of 554 women in the water group (29.1%) had an ongoing pregnancy (rate ratio, 1.37; 95% confidence interval, 1.16 to 1.61; $P < 0.001$), and 214 of 552 women in the oil group (38.8%) and 155 of 552 women in the water group (28.1%) had live births (rate ratio, 1.38; 95% CI, 1.17 to 1.64; $P < 0.001$). Rates of adverse events were low and similar in the two groups.

ELDOR-004 US PROV

[0010] Rates of ongoing pregnancy and live births were higher among women who underwent HSG with oil contrast than among women who underwent this procedure with water contrast.

[0011] HSG, which should be done in the follicular phase of the cycle, evaluates the contour of the uterine cavity, cervical canal, and tubal lumina. Other than being diagnostic, it can prove to be therapeutic. The instrument used to introduce the radio-opaque medium should be chosen to give the least discomfort and to cause no leakage of dye from the cervix. Water-soluble medium is usually used rather than an oil-based medium. Fluoroscopy with image intensification gives the best results. Insufficient dye injection will give an incomplete study. Too much dye injection, especially under pressure, might cause extravasation of the dye into the vascular system or conceal the fimbrial ends of the tubes (Baramki *et al.*, 2005).

[0012] To determine whether hysterosalpingography (HSG) increases the conception rate and to compare the therapeutic effectiveness of oil and water soluble contrast media, the histories of 744 women who attended the Yale Infertility Clinic in 1965-69 were reviewed. Exclusion of women who had been infertile less than 1 year before coming to the clinic, in whom a HSG was done outside the clinic, and in whom there was no follow-up resulted in a study population of 460. The pregnancy rate for the study group (49%) was identical to that for the larger population. The study group was divided into women who became pregnant during their clinic attendance or within 1 year of terminating clinic care and women who did not become pregnant in this period. These 2 categories were then subdivided according to whether a HSG was done. To determine the relative effectiveness of different media, the conception rate following HSG in the Yale Clinic, where the iodized oil Ethiodol was used, was compared with that among 63 women who had HSG done by a private practitioner with the water soluble dye Salpix. 221 women were in the Ethiodol HSG group, 121 (55%) of whom conceived. Of the 239 Yale Clinic patients who did not have HSG, 103 (43%) became pregnant. Exclusion of couples with organic factors that could account for infertility resulted in a pregnancy rate of 58% for the HSG group and 47% for the non-HSG group. 25 (40%) of the 63 women in the Salpix group conceived, but exclusion of couples with organic factors lowered the pregnancy rate to 38% in this group. The average length of infertility was 0.5 years longer in the non-HSG group than in the Ethiodol HSG group, but shorter in the Salpix HSG group compared to the Ethiodol group. These results suggest that Ethiodol HSG may enhance

fertility. Although the oil media has been criticized on the basis that it may cause granuloma formation or embolization, documented complications in the Yale series were rare. In contrast to earlier studies, unilateral nonpatency on x-ray was not found to affect eventual conception (58% pregnancy rate among women in the Ethiodol HSG group with normal tubes compared with 50% in those with filling of only 1 tube) (Mackey *et al.*, 1971).

[0013] Previous studies have suggested increased fertility rates following HSG using oil as compared with aqueous contrast medium. To compare the possible fertility-enhancing effects of two agents used for HSG, this prospective randomized study evaluated the subsequent fertility rates in 121 patients who underwent HSG, in which either oil or aqueous contrast medium was used. After random assignment to either agent, patients were observed for four menstrual cycles after HSG without resorting to any therapy other than clomiphene citrate where indicated. The pregnancy rates for the four cycles after HSG were compared with chi-square analysis in the total study and in the diagnostic subgroups. The subgroup with infertility of unknown cause had a significantly higher pregnancy rate after HSG with oil than after HSG with aqueous contrast medium. No significant difference was seen for any other subgroup or for the overall cohort (Schwabe *et al.*, 1983).

[0014] In a prospective randomized study, the number of pregnancies after HSG was estimated in 398 patients who had been infertile for longer than 1 year. Iohexol was used in 101 patients, ioxaglate in 102 patients, diatrizoate meglumine in 97 patients, and ethiodized poppy-seed oil in 98 patients. Ten months after HSG, the patient, referring physician, and/or hospital department was consulted for information about pregnancies. Questionnaires were obtained from the patients who became pregnant during the waiting period of 3 months. No differences in demographic parameters, infertility status, or diagnosis made with HSG were detected among the four contrast media groups. Significantly more patients became pregnant after HSG in the ethiodized poppy-seed oil group than in the three water-soluble contrast media groups ($P < 0.01$). When only intrauterine pregnancies resulting in full-term births were considered, significant differences in pregnancy rates between the oil-soluble and the water-soluble contrast media groups became more obvious. In the group that received ethiodized poppy-seed oil, almost one-third of the infertile women had normal pregnancies and childbirths after HSG (Rasmussen *et al.*, 1991).

ELDOR-004 US PROV

[0015] Meta-analysis of four randomized clinical trials (RCTs) and six nonrandomized controlled studies evaluated pregnancy rates after the use of oil- or water-soluble contrast media during HSG. Four identified RCTs studied 800 patients and six nonrandomized studies comprised an additional 1,806 patients, all experiencing primary or secondary infertility.

[0016] Pregnancy rates were significantly higher in the oil-soluble contrast media group compared with the water-soluble contrast media group in the RCTs. Inclusion of the six nonrandomized studies did not alter this conclusion. This apparent benefit was greatest for patients with unexplained infertility.

[0017] Oil-soluble contrast media have a therapeutic effect compared with water-soluble media and this effect is greatest for patients who have been diagnosed as having unexplained infertility. New techniques for the evaluation of tubal patency support the hypothesis that tubal "plugs" may be involved in proximal tubal blockage (Watson *et al.*, 1994).

[0018] Ninety-three patients with unilateral or bilateral proximal tubal occlusion confirmed by HSG or laparoscopy underwent FTR with use of water-soluble contrast material alone (n = 50) or also had an oil-based agent injected into each tube after recanalization (n = 43). Pregnancy rates and outcomes of the two groups were studied retrospectively. With respect to differences between groups, only the body mass index proved to be a significant predictor (oil, 28.4; water, 24.7; P = 0.008). Mean age, duration of infertility, type of infertility, and initial diagnosis were comparable. There was a weak trend toward a higher pregnancy rate in the oil-based contrast material group, but it was not significant (P = 0.64). The average time to pregnancy was 4.4 months with use of oil-based contrast material, compared to 7.7 months with use of only water-soluble contrast material (P = 0.03). The use of an oil-based agent had little effect on the rate of conception, but time to conception was reduced by more than 3 months (Pinto *et al.*, 2003).

[0019] HSG is used commonly in the evaluation of infertility and in the diagnosis of anomalies of the uterus and fallopian tubes. There is continued debate over the safety and diagnostic or therapeutic efficacy of water-soluble versus oil-based contrast media.

[0020] A 29-year-old woman with secondary infertility underwent HSG with both water-soluble and oil-based contrast. The fallopian tubes appeared normal. Six months later, a plain abdominal radiograph obtained at the occasion of a minor motor vehicle

accident revealed evidence of retained loculated pelvic contrast material. Subsequent laparoscopy identified adhesions and cul-de-sac implants strongly suspicious for endometriosis. Biopsy and pathologic study documented lipogranuloma.

[0021] Oil-based contrast media instilled into the pelvis at HSG can persist for prolonged periods and create granulomatous lesions mimicking endometriosis. In view of the controversy whether oil-based contrast materials are superior to water-soluble media, the routine use of oil-based contrast media should be considered carefully (Grosskinsky *et al.*, 1994).

[0022] HSG has assumed a diagnostic and possibly therapeutic role in the evaluation of the infertile couple. The procedure is done using either an oil-based (OBCM) or a water-based (WBCM) contrast medium. Data from several retrospective studies suggest that higher pregnancy rates may be achieved when OBCM is used. Interpretation of these results, however, may be confounded by various methodologic flaws in study design and comparisons of heterogeneous populations. Letterie and Rose (1990) sought to compare the therapeutic benefit of OBCM and WBCM in a prospective randomized study of infertile patients, controlling for pelvic anatomy by laparoscopic assessment. They used ethiodized oil (Ethiodol) or iothalamate meglumine (Conray 60) for tubal lavage at the time of laparoscopy only in patients with normal pelvic anatomy. Of the 225 patients who had diagnostic laparoscopy in the evaluation of infertility, 40 (18%) had normal pelvic anatomy and an otherwise unremarkable evaluation. Adequate follow-up was available on 29 patients randomized to receive either OBCM (n = 15) or WBCM (n = 14). A significant difference in pregnancy rates was noted between OBCM (40%) and WBCM (14%) by chi-square analysis. No short- or long-term adverse reactions were noted. Results of this study suggest that in patients with normal pelvic anatomy as assessed laparoscopically, OBCM may offer a therapeutic benefit not evident with WBCM.

[0023] Moore *et al.* (1990) evaluated the effect of different iodinated contrast agents on the fallopian tube and adnexal tissue in 15 rabbits. Ethiodized oil, an oil-soluble agent, was used in five rabbits. The following water-soluble agents were used: iothalamate meglumine 30% (n = 3), iothalamate meglumine 60% (n = 3), and ioxilan (n = 4). The agents were injected through catheters placed in the fallopian tubes. Fallopian tubes and peritoneal cavities were histologically evaluated. The contralateral tube served as a control. Ioxilan and iothalamate meglumine 30% produced no pathologic response in the tube or peritoneal cavity. Iothalamate meglumine 60% was associated with mild

inflammatory infiltrate, mucosal edema, giant cell reaction, and periovarian adhesions that were bilateral but more pronounced on the injected side. Use of ethiodized oil resulted in papillary fibrous adhesions on the ovarian surface, and fat granulomas were seen in the periovarian tissues. The safety of oil-based contrast agents for use in HSG is therefore questioned. No significant differences were found among the water-soluble contrast agents.

[0024] HSG can be accomplished with either oil or water-soluble contrast medium. This randomized prospective study compared pregnancy rates in women who had HSG with either water- or oil-soluble contrast material and were followed for six months. 15 of 60 (25%) patients who received water-soluble dye conceived compared with 14 of 46 (30%) patients in the oil-soluble group, a statistically insignificant difference. Furthermore, no difference in pregnancy rates within each subgroup of fertility diagnosis was detected. Intravasation was more common in patients administered oil-based contrast materials (6 of 46 versus 1 of 60 patients, $P = 0.02$), although no serious consequences occurred. No difference in the amount of pain as assessed by pain scoring was experienced by patients in each group. The authors conclude that pregnancy rates are similar after HSG with oil- and water-soluble contrast material, during at least the first six months after the procedure (Alper *et al.*, 1986).

[0025] Aspects of the immunological relationship between mother and conceptus still remain a mystery, although the recent advances in molecular biology have enlightened some of the parameters that participate in fetomaternal cross-talk during implantation (Gautam *et al.*, 2015). The atypical expression of major histocompatibility complex, the specific roles of some hormones and cytokines, as well as the temporal and spatial distributions of uterine natural killer cells, represent substantive parameters of fetomaternal immunotolerance during implantation (Oreshkova *et al.*, 2012). Although human maternal and fetal immunology is difficult to investigate, aberrant immune responses and an imbalanced cytokine network may be related to infertility, implantation failures after IVF, and recurrent pregnancy losses (Makrigiannakis *et al.*, 2011). Patients with recurrent implantation failure (RIF) should be tested for inherited and acquired thrombophilias. Each patient should be individually assessed and counseled regarding management with low-molecular-weight heparin (LMWH). Empirical treatment with LMWH, aspirin, or corticosteroids is not effective for women with RIF who have negative thrombophilic tests (Fatemi *et al.*, 2013). If thrombophilic tests are normal,

patients should be tested for immunological causes. The findings of a recent study suggest that increases in the percentage of CD56(dim) cells and NK cytotoxicity in peripheral blood may be important contributing factors for both RSA and IVF failure (Karami *et al.*, 2012). Human leukocyte antigen (HLA)-DQA1*0505 sharing or the maternal killer immunoglobulin-like receptor (KIR) repertoire is associated with recurrent spontaneous abortion (RSA) or repeated implantation failure (RIF) (Varla-Leftherioti *et al.*, 2010) and if abnormal, the patient might then benefit from intravenous immunoglobulin (IVIg) therapy (Fatemi *et al.*, 2013). IVIg has been successful in the treatment of recurrent miscarriage and recurrent implantation failure among women with elevated anti-phospholipid antibodies (APA) and/or NK cell activity (Coulam *et al.*, 2012). When the pregnancy outcomes of women with a history of reproductive failure and elevated NK cell cytotoxicity treated with intralipid were compared with women treated with IVIg, no differences were seen. Side-by-side comparison showed that synthetic pre-implantation factor (sPIF) is equally effective to inhibit NK cell toxicity at a lower dose than intravenous gamma immunoglobulin or intralipid treatment currently used (Roussev *et al.*, 2013). sPIF is not yet available commercially, but intralipid infusions are available globally. Intralipid is a synthetic product composed of 10 % soybean oil, 1,2 % egg yolk phospholipids, 2.25 % glycerin, and water. When indicated, IL is infused 7-10 days prior to embryo transfer, and one more time again after a positive pregnancy in women whose NKa is due to an autoimmune causes (antiphospholipid antibodies and/or antithyroid antibodies) (CARE Fertility Forum Index). In cases of alloimmune implantation dysfunction (DQa and/HLA matching between the embryo recipient and the male partner), the same applies, but in this situation, the infusion is repeated at 2-4 week intervals until the 24th week of pregnancy. IL costs about 10 times less than IVIg, is not a blood product, and is without significant side effects (CARE Fertility Forum Index).

Conclusion

[0026] It is the first time that intralipid-iodine is suggested to be used for HSG in infertile women.

REFERENCES

1. D. Hallberg I. *et al.*, Fat emulsions for complete intravenous nutrition, *Postgrad. med. J.* 1967, 43, 307-316.
2. Juras J *et al.*, Imaging in tubal infertility, *Rev Prat* 2002, 2:1768-74.
3. Elstein M., Tubal disease and fertility outcome., *Reprod Biomed Online* 2008, 16:167-9.
4. Thurmond AS *et al.*, A Review of Selective Salpingography and Fallopian Tube Catheterization, *RadioGraphics* 2000, 20:1759-68
5. Papaioannou S. *et al.*, Diagnostic and therapeutic value of selective salpingography and tubal catheterization in an unselected infertile population, *Fertil steril* 2003, 79: 613-7.
6. Dreyer K. *et al.*, Oil-Based or Water-Based Contrast for Hysterosalpingography in Infertile Women, *N. Engl. J. Med.* 2017, 376(21):2043-2052.
7. Baramki TA. Hysterosalpingography, *Fertil Steril.* 2005 Jun;83(6):1595-606.
8. Mackey RA *et al.*, Pregnancy following hysterosalpingography with oil and water soluble dye, *Fertil Steril.* 1971, 22(8):504-7.
9. Schwabe MG *et al.*, Hysterosalpingography with oil contrast medium enhances fertility in patients with infertility of unknown etiology, *Fertil. Steril.* 1983, 40(5):604-6.
10. Rasmussen F *et al.*, Therapeutic effect of hysterosalpingography: oil- versus water-soluble contrast media--a randomized prospective study, *Radiology*, 1991, 179(1): 75-8.
11. Watson A *et al.*, A meta-analysis of the therapeutic role of oil soluble contrast media at hysterosalpingography: a surprising result?, *Fertil Steril.* 1994, 61(3):470-7.
12. Pinto AB *et al.*, Pregnancy outcomes after fallopian tube recanalization: oil-based versus water-soluble contrast agents, *J Vasc Interv Radiol.* 2003, 14(1):69-74.
13. Grosskinsky CM *et al.*, Pelvic granulomata mimicking endometriosis following the administration of oil-based contrast media for hysterosalpingography, *Obstet Gynecol.* 1994, 83(5 Pt 2):890-2.
14. Letterie GS & Rose GS, Pregnancy rates after the use of oil-based and water-based contrast media to evaluate tubal patency, *South Med J.* 1990, 83(12):1402-3.
15. Moore DE *et al.*, Effects of contrast agents on the fallopian tube in a rabbit model, *Radiology.* 1990, 176(3):721-4.

16. Alper MM *et al.*, Pregnancy rates after hysterosalpingography with oil- and water-soluble contrast media. *Obstet Gynecol*, 1986, 68(1):6-9.
17. Gautam N. Allahbadia, Intralipid Infusion is the Current Favorite of Gynecologists for Immunotherapy, *J. Obstet. Gynaecol. India*. 2015, 65(4): 213-217.
18. Oreshkova T *et al.*, A cross-talk of decidual stromal cells, trophoblast, and immune cells: a prerequisite for the success of pregnancy, *Am. J. Reprod. Immunol*. 2012;68(5):366–373.
19. 18. Makrigiannakis A, Petsas G, Toth B, et al. Recent advances in understanding immunology of reproductive failure. *J Reprod Immunol*. 2011, 90(1):96-104.
20. Fatemi H. *et al.*, Implantation in assisted reproduction: a look at endometrial receptivity, *Reprod Biomed Online*. 2013, 27(5):530-538.
21. Karami N. *et al.*, Enhancement of peripheral blood CD56(dim) cell and NK cell cytotoxicity in women with recurrent spontaneous abortion or in vitro fertilization failure, *J. Reprod. Immunol*. 2012, 95(1-2):87-92.
22. Varla-Leftherioti M. *et al.*, HLA-DQA1*0505 sharing and killer immunoglobulin-like receptors in sub fertile couples: report from the 15th International Histocompatibility Workshop, *Tissue Antigens*. 2010, 75(6):668-672.
23. Coulam CB *et al.*, Does immunotherapy for treatment of reproductive failure enhance live births?, *Am. J. Reprod. Immunol*. 2012, 67(4):296-304.
24. Roussev RG *et al.*, Preimplantation factor inhibits circulating natural killer cell cytotoxicity and reduces CD69 expression: implications for recurrent pregnancy loss therapy, *Reprod Biomed Online*. 2013, 26(1):79-87.
25. CARE Fertility Forum Index. Intralipids- All you need to know. <http://www.carefertility.com/ivf/viewtopic.php?t=39200>.

CLAIMS

1. A multidisciplinary and multipotent intralipid-iodine for use in imaging.
2. The intralipid-iodine according to claim 1, wherein said imaging is hysterosalpingography in infertile women.
3. The intralipid-iodine according to claim 1, wherein said imaging is X-ray imaging or cardiac- and limbs-catheterization.
4. The intralipid-iodine according to any one of the preceding claims, wherein said intralipid-iodine is formulated for injection into the blood stream of a patient.
5. The intralipid-iodine according to any one of the preceding claims, which is any lipid emulsion.
6. The intralipid-iodine according to any one of the preceding claims, wherein said intralipid-iodine absorbs / attaches obstructive or potentially-obstructive particles located within blood vessels and/or other organs in the body, and removes same to thereby open clogged blood vessels.
7. A multidisciplinary and multipotent composition comprising intralipid-iodine for use in imaging.
8. The composition according to claim 7, further comprising a pharmaceutically acceptable carrier adapted for injection.
9. The composition according to claim 7 or 8, which is formulated for administration into the blood stream.
10. The composition according to any one of claims 7-9, wherein said intralipid-iodine is any lipid emulsion.

ELDOR-004 US PROV

11. The composition according to any one of claims 7-10, wherein said intralipid-iodine absorbs / attaches obstructive or potentially-obstructive particles located within blood vessels and/or other organs in the body, and removes same to thereby open clogged blood vessels.
12. A method for imaging comprising administering to an individual in need thereof an effective amount of intralipid-iodine or a composition comprising same.
13. The method according to claim 12, comprising injecting said intralipid-iodine or said composition comprising same into the blood stream of said individual.
14. The method according to any one of claims 12-13, wherein said intralipid-iodine is any lipid emulsion.
15. The method according to any one of claims 12-14, wherein said intralipid-iodine absorbs / attaches obstructive or potentially-obstructive particles located within blood vessels and/or other organs in the body, and removes same to thereby open clogged blood vessels.
16. An intravenous composition comprising intralipid-iodine for use in imaging.
17. The composition according to claim 16, further comprising a pharmaceutically acceptable carrier adapted for injection.
18. The composition according to claim 16 or 17, wherein said intralipid-iodine absorbs / attaches obstructive or potentially-obstructive particles located within blood vessels and/or other organs in the body, and removes same to thereby open clogged blood vessels.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

Table with 6 columns: APPLICATION NUMBER (62/529,073), FILING or 371(c) DATE (07/06/2017), GRP ART UNIT, FIL FEE REC'D (130), ATTY.DOCKET.NO (ELDOR4), TOT CLAIMS, IND CLAIMS

1444
Browdy and Neimark, PLLC
1625 K Street, N.W.
Suite 1100
Washington, DC 20006

CONFIRMATION NO. 7883
FILING RECEIPT



Date Mailed: 07/11/2017

Receipt is acknowledged of this provisional patent application. It will not be examined for patentability and will become abandoned not later than twelve months after its filing date. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

Inventor(s) Joseph Eldor, Jerusalem, ISRAEL;

Applicant(s) Joseph Eldor, Jerusalem, ISRAEL;

Power of Attorney: Ronni Jillions--31979

Permission to Access Application via Priority Document Exchange: Yes

Permission to Access Search Results: Yes

Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as appropriate.

If Required, Foreign Filing License Granted: 07/11/2017

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US 62/529,073

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

INTRALIPID-IODINE FOR IMAGING

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit <http://www.SelectUSA.gov> or call +1-202-482-6800.